About US
Contact us
-
China's Cabinet approves plan to strengthen drug safetyThe State Council, or the Cabinet, on Wednesday （December 7, 2011）approved a blueprint to establish a credit rating system and intensify monitoring for pharmaceutical groups to boost the country's dru2011/12/12
-
Merck to establish China research headquartersUS-based pharmaceutical major Merck & Co is planning to establish a research and development headquarters in Beijing, China, spearheading a five-year investment into research in China worth approx2011/12/9
-
UPDATE 2-AstraZeneca slashes 1,150 U.S. sales jobs* Cuts represent 24 pct of U.S. sales force * Cost of $50-100 mln won't impact 2011 core EPS By Paul Sandle and Ben Hirschler LONDON, Dec 7 (Reuters) - AstraZeneca is cutting nearly a quarter2011/12/9
-
'Me-too' pharma firms will 'disappear' - Roche's SchwanDrugmakers whose offerings do not offer any genuine value are going to "literally disappear" over the next decade, according to Roche's chief executive. Speaking at the FT Pharmaceutical and Biotec2011/12/8
-
China approves plan to strengthen drug safetyBEIJING - The State Council, or the Cabinet, on Wednesday approved a blueprint to establish a credit rating system and intensify monitoring for pharmaceutical groups to boost the country's drug safety2011/12/8
-
Sanofi criticizes study flagging Lantus cancer risk(Reuters) - A Swedish study has rekindled concerns about a possible link between Sanofi's top-selling insulin drug Lantus and cancer, but the French drugmaker said on Wednesday the observational resea2011/12/8
-
Guidance on Management of Laboratory for Drug Clinical Trial Biological Sample Analysis (interim) issuedTo enhance the management of laboratories for drug clinical trial biological sample analysis, and improve the quality and management of analytical data of biological samples, the State Food and Drug A2011/12/7
-
SFDA issues Guideline on Management of Phase I Clinical Trial of Drugs (interim)To enhance the management of the Phase I clinical trial of drugs, effectively safeguard the rights, benefits and safety of trial subjects, and improve the research quality and management of the Phase2011/12/7
-
Abbott dismisses talk of pharma unit saleDec 5 (Reuters) - Abbott Laboratories has no intention of selling its soon-to-be-separated pharmaceuticals business to another drugmaker and any potential bidder would struggle to persuade management2011/12/6
-
Back pain, arthritis to dominate chronic pain market: studyDrugs for the treatment of chronic back pain and arthritis-related pain will continue to be the most lucrative segments of the market for chronic pain treatments up to 2020, according to new forecasts2011/12/6